Archives

Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting

B BOSTON, April 28, 2026 /PRNewswire/ — Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster…

Read MoreAscidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting